Massive heart surgery trial aims to slash infection rates
NCT ID NCT06567808
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding a second antibiotic (vancomycin) to the standard one (cefazolin) or giving antibiotics for a longer time can prevent serious infections after open-heart surgery. About 38,000 adults having heart surgery will be randomly assigned to one of four antibiotic plans. The goal is to find the safest and most effective way to stop surgical site infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 38,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Adult patients (≥18 years of age) undergoing open-heart surgery (i.e. sternotomy, including minimally-invasive surgical techniques through mini-sternotomies) Exclusion Criteria: 1. On systemic antibiotics or with an active bacterial infection at the time of surgery 2. Previously enrolled in this trial 3. Known to be colonized with methicillin-resistant staphylococcus aureus (MRSA). Where it is unethical to not administer glycopeptides. 4. Beta-lactam or vancomycin allergy precluding the use of cefazolin or vancomycin, respectively 5. Participation in other studies that may interfere with this trial. 6. Patients undergoing cardiac transplant
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Infection, surgical site are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.